Articles

Rewarding the best in digital innovation

17th September 2014

Rewarding the best in digital innovation  Rachel Farrow

With the PM Society's annual Digital Awards set to take place next week, pharmaphorum talks to co-chair of the Society and chair of the awards, Rachel Farrow, to get the... Read more

Korea holds advantages for clinical trial research

16th September 2014

Korea holds advantages for clinical trial researchAmes Gross

A supportive government, modern infrastructure and easily accessible patient population are helping this Asian nation become a top location for clinical trial research.South Korea, a country in Northeast Asia with... Read more

UK Prix Galien: Astellas C. diff drug on innovation shortlist

15th September 2014

UK Prix Galien: Astellas C. diff drug on innovation shortlistStaff reporter

This article is the first in a series investigating some of the shortlisted products in the prestigious UK Prix Galien awards, and their potential impact on health services. Prior to... Read more

Selling science to potential investors and partners

12th September 2014

Selling science to potential investors and partnersSteve Mather

Start-ups and biotechs often need the support of outside investors to take their innovations to the next level. So what are the considerations when preparing a presentation for these important... Read more

News

AstraZeneca to work with Lilly on Alzheimer's drug

16th September 2014

AstraZeneca to work with Lilly on Alzheimer's drugAndrew McConaghie

AstraZeneca has enlisted the help of Lilly in the development of its new Alzheimer's candidate AZD3293.The drug is an oral beta secretase cleaving enzyme (BACE) inhibitor, which the companies plan... Read more

Side effect fears weigh on Merck osteoporosis drug

16th September 2014

Side effect fears weigh on Merck osteoporosis drugStaff reporter

Positive efficacy data for Merck's osteoporosis drug candidate odanacatib have been undermined by doubts about safety and a decision to hold back filing of the drug until mid-2015.Merck (known as... Read more

Novel AR drug hope for prostate cancer

16th September 2014

Novel AR drug hope for prostate cancerLinda Banks

Bayer HealthCare and Orion Corporation are enrolling prostate cancer patients in a phase III trial with ODM-201, an investigational oral androgen receptor (AR) inhibitor.The study, ARAMIS, is set to evaluate... Read more

EFPIA hails joint action on counterfeit drugs

15th September 2014

EFPIA hails joint action on counterfeit drugsLinda Banks

The European Federation of Pharmaceutical Industries and Associations (EFPIA) is backing the European Stakeholder Model (ESM) as a means to combat the resale of stolen and counterfeit drugs in the... Read more

Audio & Video

Live webinar: Is pharma brand marketing …

Kantar Health webinar


While pharma observers speculate on the death of outdated drug discovery and sales models, some critical wounds to brand marketing have been... View more

Tweetchat: Managing diabetes in the real…

Atlantis Healthcare diabetes Tweetchat


Atlantis Healthcare is working with pharmaphorum to conduct a Tweetchat on the real world challenges patients face in managing... View more

Patient Opinion Leaders: Andrew Schorr

 

As a cancer survivor and passionate patient advocate, Andrew Schorr typifies the concept of a Patient Opinion Leader (POL). He is a contributor to the... View more

View the recorded webinar - The future o…

WEBINAR COVER smaller


The global pharmaceutical market passes a significant milestone in 2014: reaching one trillion US dollars in total value. IMS Health... View more

White Papers

Diabetes in France

Diabetes in FranceJanet Gunner

Analysis of open social media in relation to a particular disease area can provide useful intelligence on how different treatments and pharmaceutical companies are perceived, by both doctors and patients,... View info

Diabetes in Germany

Diabetes in GermanyJanet Gunner

Analysis of open social media in relation to a particular disease area can provide useful intelligence on how different treatments and pharmaceutical companies are perceived, by both doctors and patients,... View info

Connected data and the use of smartphone…

Connected data and the use of smartphone enabled apps in market researchPaul Mannu

Rapid growth in smartphone usage offers healthcare researchers a useful tool to gain better understanding of how patients and healthcare professionals actually behave on a daily basis. Inaccuracies can arise... View info

Diabetes in the UK

Diabetes in the UKJanet Gunner

Analysis of open social media in relation to a particular disease area can provide useful intelligence on how different treatments and pharmaceutical companies are perceived, by both doctors and patients,... View info

Further News & Articles

Gilead signs Sovaldi generics deal for 91 developing countries

Gilead has signed a deal with seven India-based generics firms which will see them manufacture hepatitis C dr... Read more

News

Daclizumab HYP tops Avonex in multiple sclerosis trial

Biogen Idec and AbbVie's multiple sclerosis candidate daclizumab HYP has moved a little closer to approval after... Read more

News

Xtandi approved as first line prostate cancer treatment

Prostate cancer drug Xtandi has been given FDA approval for use as a first line treatment for metastatic castrat... Read more

News

Lung cancer vaccine to enter clinical trials

Cancer Research UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, ar... Read more

News

Safety warnings will hold back new obesity treatment Contrave

Takeda and Orexigen have been given FDA clearance to market their obesity treatment Contrave – but sales of t... Read more

News

Apple puts health at the heart of its new smartwatch

After months of speculation, Apple finally unveiled its smartwatch that - when paired with an iPhone - promis... Read more

News